DEVELOPMENT AND COMMERCIAL LICENSE AGREEMENT By and Among BAXALTA INCORPORATED, BAXALTA US INC., BAXALTA GMBH, and PRECISION BIOSCIENCES, INC.Development and Commercial License Agreement • March 13th, 2019 • Precision Biosciences Inc • Biological products, (no disgnostic substances) • New York
This DEVELOPMENT AND COMMERCIAL LICENSE AGREEMENT (together with the exhibits and schedules hereto, as may be amended pursuant hereto, collectively, this “Agreement”) is entered into on this 24th day of February, 2016 (the “Effective Date”), by and among BAXALTA INCORPORATED, a Delaware corporation with its principal place of business at 1200 Lakeside Drive, Bannockburn, IL 60015 (“BI”), BAXALTA US INC., a Delaware corporation with its principal place of business at 1200 Lakeside Drive, Bannockburn, IL 60015 (“BUSI”), BAXALTA GMBH, a company organized under the laws of Switzerland with its principal place of business at Postfach 8010, Zurich, Switzerland (“BGMBH” and, together jointly and severally with BI and BUSI, collectively, “Baxalta”), and PRECISION BIOSCIENCES, INC., a Delaware corporation with its principal place of business at 302 E Pettigrew St A-100, Durham, NC 27701 (“Precision”). Baxalta and Precision may each be referred to herein individually as a “Party” and collectivel
AMENDMENT NO. 6 TO DEVELOPMENT AND COMMERCIAL LICENSE AGREEMENTDevelopment and Commercial License Agreement • November 10th, 2020 • Precision Biosciences Inc • Biological products, (no disgnostic substances)
This AMENDMENT NO. 6 TO DEVELOPMENT AND COMMERCIAL LICENSE AGREEMENT (this “Amendment”), effective as of October 2, 2020, amends that certain Development and Commercial License Agreement, effective February 24, 2016 (as previously amended by that certain Amendment No. 1 to Development and Commercial License Agreement, effective as of February 24, 2017, that certain Amendment No. 2 to Development and Commercial License Agreement, effective as of August 21, 2017, that certain Amendment No. 3 to Development and Commercial License Agreement, effective as of February 5, 2018, that certain Amendment No. 4 to Development and Commercial License Agreement, effective as of May 23, 2018, and that certain Amendment No. 5 to Development and Commercial License Agreement, effective as of September 18, 2019, the “DCLA”), by and among LES LABORATOIRES SERVIER, a corporation incorporated under the laws of France having a principal place of business at 50 rue Carnot, 92150 Suresnes, France (“LLS”) and IN
DEVELOPMENT AND COMMERCIAL LICENSE AGREEMENT By and among STARTON THERAPEUTICS, INC. and HAISCO PHARMACEUTICAL GROUP CO., LTDDevelopment and Commercial License Agreement • July 13th, 2023 • HWEL Holdings Corp. • Pharmaceutical preparations
This DEVELOPMENT AND COMMERCIAL LICENSE AGREEMENT (together with all Exhibits, this “Agreement”) is entered into on this 10th day of February, 2021 (the “Effective Date”), by and among STARTON THERAPEUTICS, INC., a Delaware corporation with its principal place of business at 215 College Road, Suite 300, Paramus, New Jersey 07652 (“Starton”), and HAISCO PHARMACEUTICAL GROUP Co., Ltd., a corporation incorporated under the laws of the People’s Republic of China with its principal place of business at No. 136 Baili Road CNSTP, Wenjiang District, Chengdu, Sichuan Province 611130 (“Haisco”). Haisco and Starton may each be referred to herein individually as a “Party” and collectively as the “Parties.”
